[Research] Samsung Biologics (207940) – IBK Securities | Plant 5 Ramp-up · Resolution of Labor Risk · Annual Guidance Delivery / 2026-06-29
Brokerage : IBK Securities Analyst : Yisoo Jung, CFA Investment Rating : BUY (Maintained) Target Price : KRW 2,090,000 (Maintained) Core Momentum : Despite temporary labor strike impacts, structural revenue visibility is expected to remain intact supported by favorable FX rates, revenue contribution from the Rockville site, and Plant 5 ramp-up in the second half….